Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented City Therapeutics in the transaction. City Therapeutics, a biopharmaceutical company, announced raising $135 million in Series A financing...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Veradigm Inc. in the transaction, and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented ScienceIO. Veradigm Inc. (NASDAQ: MDRX) (the “Company”),...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented ARCH Venture Partners on the deal. ARCH Venture Partners led the $270 million Series A financing of Orbital Therapeutics, a company focused on enhancing...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Colossal Biosciences on the deal. Colossal Biosciences, a genetic engineering company, announced its $150 million Series B financing led by United States Innovative Technology...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented client Section 32 on the deal while Wilson Sonsini advised BigHat Biosciences. Section 32, a venture capital fund that invests in frontiers of...
You must be a Standard 1 Year member to access this content.
